Optomed (OPTOMED) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue declined 26.3% to €3.1M due to absence of large device orders and weaker device sales in China and distributor channels.

• FY24 revenue outlook revised from growth to decline, reflecting challenging market conditions.

• Aurora AEYE commercialization is progressing, with FDA clearance and CE marking for the next-generation handheld camera.

• Software segment remained relatively stable, down 4.0% year-over-year, with a significant dental imaging win expected to contribute from 2025.

• Cash position at end of Q3 €11M, supported by a €7.9M share issue in June 2024.

Financial highlights

• Q3 2024 revenue €3.1M, down 26.3% year-over-year; Q1–Q3 2024 revenue €9.9M, down 13.1%.

• Q3 EBITDA -€0.8M (margin -26.2%), net loss -€1.6M, EPS -€0.09.

• Q1–Q3 2024 net loss -€4.5M.

• Q3 gross margin 54.4% (down from 67.4%), mainly due to inventory revaluation.

• Cash and cash equivalents at period end: €11M; net debt: -€8.3M.

Outlook and guidance

• Full-year 2024 revenue expected to decrease from 2023; previous guidance anticipated growth.